Agenus | AGEN - Cash And Equivalent


Agenus reported $35M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Agenus USD 35M 32M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Celldex Therapeutics USD 35.73M 6.86M Mar/2026
CSL USD 2.16B 633M Jun/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Glaxosmithkline GBP 3.3B 303M Sep/2025
Incyte USD 4.02B 435.22M Mar/2026
Intrexon USD 9.34M 1.77M Jun/2024
J&J USD 21.69B 1.98B Mar/2026
Jiangsu Hengrui CNY 40.96B 591.41M Dec/2025
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
MacroGenics USD 66.52M 9.3M Mar/2026
Merck EUR 2.33B 77M Dec/2025
Merck USD 5.33B 9.24B Mar/2026
Northwest Biotherapeutics USD 4.56M 244K Sep/2025
Novartis USD 6.88B 4.56B Mar/2026
Novavax USD 228.36M 12.27M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Veracyte USD 263.14M 99.44M Mar/2026